154 related articles for article (PubMed ID: 30593980)
61. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
[TBL] [Abstract][Full Text] [Related]
62. Cognitive but not affective theory of mind deficits in mild relapsing-remitting multiple sclerosis.
Roca M; Manes F; Gleichgerrcht E; Ibáñez A; González de Toledo ME; Marenco V; Bruno D; Torralva T; Sinay V
Cogn Behav Neurol; 2014 Mar; 27(1):25-30. PubMed ID: 24674963
[TBL] [Abstract][Full Text] [Related]
63. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
Sundgren M; Piehl F; Wahlin Å; Brismar T
Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
[TBL] [Abstract][Full Text] [Related]
64. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
Broicher SD; Filli L; Geisseler O; Germann N; Zörner B; Brugger P; Linnebank M
J Neurol; 2018 May; 265(5):1016-1025. PubMed ID: 29464379
[TBL] [Abstract][Full Text] [Related]
65. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment.
Romani A; Bergamaschi R; Candeloro E; Alfonsi E; Callieco R; Cosi V
Mult Scler; 2004 Aug; 10(4):462-8. PubMed ID: 15327047
[TBL] [Abstract][Full Text] [Related]
66. Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.
Bertoglio JC; Baumgartner M; Palma R; Ciampi E; Carcamo C; Cáceres DD; Acosta-Jamett G; Hancke JL; Burgos RA
BMC Neurol; 2016 May; 16():77. PubMed ID: 27215274
[TBL] [Abstract][Full Text] [Related]
67. An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol.
Jongen PJ; Heerings M; Ruimschotel R; Hussaarts A; Evers S; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Lemmens WA; Donders R; van der Zande A; Visser LH
BMC Neurol; 2016 May; 16():81. PubMed ID: 27234001
[TBL] [Abstract][Full Text] [Related]
68. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
Liu G; Weinger JG; Lu ZL; Xue F; Sadeghpour S
J Alzheimers Dis; 2016; 49(4):971-90. PubMed ID: 26519439
[TBL] [Abstract][Full Text] [Related]
70. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
López-Góngora M; Querol L; Escartín A
BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
[TBL] [Abstract][Full Text] [Related]
71. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
[TBL] [Abstract][Full Text] [Related]
72. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
[TBL] [Abstract][Full Text] [Related]
73. Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability.
Migliore S; Ghazaryan A; Simonelli I; Pasqualetti P; Squitieri F; Curcio G; Landi D; Palmieri MG; Moffa F; Filippi MM; Vernieri F
Behav Neurol; 2017; 2017():7404289. PubMed ID: 28912625
[TBL] [Abstract][Full Text] [Related]
74. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
75. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
76. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
Bever CT; Young D; Anderson PA; Krumholz A; Conway K; Leslie J; Eddington N; Plaisance KI; Panitch HS; Dhib-Jalbut S
Neurology; 1994 Jun; 44(6):1054-9. PubMed ID: 8208399
[TBL] [Abstract][Full Text] [Related]
77. Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
Doraiswamy PM; Babyak MA; Hennig T; Trivedi R; White WD; Mathew JP; Newman MF; Blumenthal JA
Psychopharmacol Bull; 2007; 40(2):54-62. PubMed ID: 17514186
[TBL] [Abstract][Full Text] [Related]
78. Indices of cognitive dysfunction in relapsing-remitting multiple sclerosis: intra-individual variability, processing speed, and attention network efficiency.
Wojtowicz M; Omisade A; Fisk JD
J Int Neuropsychol Soc; 2013 May; 19(5):551-8. PubMed ID: 23425598
[TBL] [Abstract][Full Text] [Related]
79. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study.
Jensen HB; Nielsen JL; Ravnborg M; Dalgas U; Aagaard P; Stenager E
Mult Scler Relat Disord; 2016 Nov; 10():137-144. PubMed ID: 27919481
[TBL] [Abstract][Full Text] [Related]
80. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M;
Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
